Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Systemic Lupus Erythematosus
Clinical trial register · United States · industry-sponsored

Systemic Lupus Erythematosus Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 27 Florida 27 Illinois 18 Alabama 15 Georgia 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca8 Novartis Pharmaceuticals4 GlaxoSmithKline3 AbbVie3 Bristol-Myers Squibb2
State
California27 Florida27 Illinois18 Alabama15 Georgia14
All 37 states
Target enrolment
to

Systemic Lupus Erythematosus trials in the USA

42 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
NCT07570862Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III
DrugFT819
Fate Therapeutics
Phase 2
53
California, Florida, Nebraska, North Carolina, Texas
2026-07-27
Recruiting
US Zamto-cel Autoimmune Diseases
NCT06708845Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
DrugsZamtocabtagene autoleucel·Fludarabine·Cyclophosphamide
Miltenyi Biomedicine GmbH
Phase 1
48
Wisconsin
2026-07
Recruiting
Anifrolumab Pregnancy Study
NCT07049653Systemic Lupus Erythematosus
AstraZeneca
Observational
500
North Carolina
2026-06-04
Recruiting
AbbVie
Phase 1
30
Alabama, California, Florida, Illinois, Tennessee, Texas
2026-05-28
Recruiting
Boehringer Ingelheim
Phase 2
405
California, Colorado, Florida, Michigan, Mississippi, Montana, North Carolina, Ohio
2026-04-20
Recruiting
AstraZeneca
Phase 3
245
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-04-13
Recruiting
AstraZeneca
Phase 4
16
Nevada
2026-01-16
Recruiting
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New Mexico, New York, Tennessee
2025-12-03
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Alabama, California, Florida, Missouri, Texas
2025-12-02
By invitation
Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)
NCT07221565Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases
DrugNaltrexone
Truway Health, Inc.
Phase 1/2
120
New York
2025-10-23
Recruiting
AbbVie
Phase 1
36
Florida, Illinois, Tennessee, Texas
2025-08-26
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Arizona, Colorado, Florida, Louisiana, Massachusetts, Minnesota, New York, Ohio
2025-07-16
Recruiting
Climb Bio, Inc.
Phase 1
30
Texas
2025-07-10
By invitation
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
NCT07038447Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis, Idiopathic Inflammatory Myopathy
DrugsKITE-363·Fludarabine·Cyclophosphamide
Kite, A Gilead Company
Phase 1
52
California, Florida, New York
2025-07-02
Recruiting
AstraZeneca
Observational
442
North Carolina
2025-07-01
Recruiting
AstraZeneca
Phase 1
72
Alabama, California, Iowa, Nebraska, North Carolina
2025-05-01
Active, closed
Synthekine
Phase 1
48
Arizona, New Jersey, New York, Ohio
2025-04-29
Recruiting
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
NCT06340750Systemic Lupus Erythematosus
DrugBaff Car-T
Luminary Therapeutics
Phase 1
18
Ohio
2025-04-01
Active, closed
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
NCT06255028Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
DrugAldesleukin
Century Therapeutics, Inc.
Phase 1
6
California, Illinois, Texas, Utah, Washington
2025-02-06
Recruiting
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
NCT06737380SLE, Lupus, Systemic Lupus Erthematosus, Systemic Lupus Erythematosus
LiveKidney.Bio
Phase 1
10
South Carolina
2025-01-07
Recruiting
UCB Biopharma SRL
Phase 3
450
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-11-21
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
190
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland
2024-09-17
Recruiting
GlaxoSmithKline
Phase 1
142
Arizona, Colorado, Nevada, Ohio, Oklahoma, Texas
2024-09-02
Active, closed
Novartis Pharmaceuticals
Phase 2
155
Alabama, California, Florida, Georgia, Indiana, Louisiana, Michigan, Ohio
2024-07-02
Active, closed
GlaxoSmithKline
Phase 4
303
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan
2024-06-06
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2024-05-21
Active, closed
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
NCT06294236Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
DrugsSC291·Fludarabine·Cyclophosphamide
Sana Biotechnology
Phase 1
7
Colorado, Georgia, Maryland, Massachusetts, Washington
2024-04-29
Recruiting
AstraZeneca
Phase 3
100
Arizona, California, District of Columbia, Illinois, Louisiana, Maryland, Minnesota, New York
2024-03-14
Recruiting
Cabaletta Bio
Phase 1/2
28
California, Connecticut, Florida, Georgia, Illinois, Kansas, Massachusetts, Minnesota
2024-02-16
Active, closed
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
270
Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri, Nebraska
2023-09-13
Active, closed
AbbVie
Phase 3
1,014
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-07-25
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Alabama, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland
2023-04-21
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-03-02
Active, closed
Bristol-Myers Squibb
Phase 3
513
California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan, Minnesota
2023-01-12
Active, closed
Bristol-Myers Squibb
Phase 3
516
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-01-12
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
379
California, Florida, Indiana, Michigan, Minnesota, Ohio, Tennessee
2022-09-16
Active, closed
Sanofi
Phase 2
109
Alabama, Arizona, California, Florida, New Mexico, New York, Oklahoma, Tennessee
2021-11-10
Active, closed
Hoffmann-La Roche
Phase 3
303
Alabama, Arkansas, California, Florida, Michigan, New York, North Carolina, Ohio
2021-10-26
Active, closed
Beeline Medicines Corporation
Phase 2
248
Alabama, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland
2021-10-11
By invitation
UCB Biopharma SRL
Phase 3
760
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2021-07-27
Active, closed
AstraZeneca
Phase 3
367
Alabama, Arizona, California, Colorado, Florida, Idaho, Michigan, New Jersey
2021-06-08
Active, closed
GlaxoSmithKline
Phase 2
25
Ohio
2019-11-28
Rows per page Showing 1–42 of 42
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/systemic-lupus-erythematosus

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 42 of those studies listing the condition Systemic Lupus Erythematosus.

How many Systemic Lupus Erythematosus trials are recruiting in the US?

21 of the 42 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 18 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Systemic Lupus Erythematosus), 42 studies
PhaseStudiesRecruitingShare
Phase 114933.3%
Phase 312428.6%
Phase 210423.8%
Observational224.8%
Phase 1/2214.8%
Phase 4214.8%

Most active sponsors

Lead sponsors with the most studies (Systemic Lupus Erythematosus)
Lead sponsorStudiesRecruiting
AstraZeneca87
Novartis Pharmaceuticals41
AbbVie32
GlaxoSmithKline31
Bristol-Myers Squibb20
UCB Biopharma SRL21
Amgen11
Beeline Medicines Corporation10
Boehringer Ingelheim11
Cabaletta Bio11

Top states

Top states (Systemic Lupus Erythematosus), by number of studies with a site there
StateStudies
California27
Florida27
Illinois18
Alabama15
Georgia14
Arizona13
Colorado12
Louisiana10
Michigan9
Ohio9
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.